Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Kyverna Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Kyverna Therapeutics, Inc.’s stock price such as:

• Kyverna Therapeutics, Inc.’s current stock price and volume
• Why Kyverna Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for KYTX from analysts
• KYTX’s stock price momentum as measured by its relative strength

About Kyverna Therapeutics, Inc. (KYTX)

Before we jump into Kyverna Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Want to learn more about Kyverna Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Kyverna Therapeutics, Inc..

Kyverna Therapeutics, Inc.’s Stock Price as of Market Close

As of December 05, 2025, 4:00 PM, CST, Kyverna Therapeutics, Inc.’s stock price was $7.800.

Kyverna Therapeutics, Inc. is down 0.51% from its previous closing price of $7.840.

During the last market session, Kyverna Therapeutics, Inc.’s stock traded between $7.770 and $8.080. Currently, there are approximately 43.42 million shares outstanding for Kyverna Therapeutics, Inc..

Kyverna Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Kyverna Therapeutics, Inc. Stock Price History

Kyverna Therapeutics, Inc.’s (KYTX) price is currently up 1.69% so far this month.

During the month of December, Kyverna Therapeutics, Inc.’s stock price has reached a high of $8.190 and a low of $6.450.

Over the last year, Kyverna Therapeutics, Inc. has hit prices as high as $8.447 and as low as $1.780. Year to date, Kyverna Therapeutics, Inc.’s stock is up 108.56%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Kyverna Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there was 1 analyst who downgraded Kyverna Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Kyverna Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Kyverna Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Kyverna Therapeutics, Inc. (KYTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Kyverna Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Kyverna Therapeutics, Inc. has a weighted four-quarter relative price strength of 30.67%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Kyverna Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Kyverna Therapeutics, Inc. Stock Price: Bottom Line

As of December 5, 2025, Kyverna Therapeutics, Inc.’s stock price is $7.800, which is down 0.51% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Kyverna Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.